ID   PP2BA_RAT               Reviewed;         521 AA.
AC   P63329; P12816; P20652; Q6LDJ8; Q9WUV7; Q9Z1I5;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   02-OCT-2024, entry version 168.
DE   RecName: Full=Protein phosphatase 3 catalytic subunit alpha {ECO:0000312|RGD:3382};
DE            EC=3.1.3.16 {ECO:0000269|PubMed:1322410, ECO:0000269|PubMed:24018048};
DE   AltName: Full=CAM-PRP catalytic subunit;
DE   AltName: Full=Calcineurin A alpha {ECO:0000303|PubMed:1335233};
DE   AltName: Full=Calmodulin-dependent calcineurin A subunit alpha isoform {ECO:0000250|UniProtKB:P63328};
DE            Short=CNA alpha {ECO:0000250|UniProtKB:P63328};
DE   AltName: Full=Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform {ECO:0000250|UniProtKB:Q08209};
GN   Name=Ppp3ca {ECO:0000312|RGD:3382}; Synonyms=Calna;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2551293; DOI=10.1016/0006-291x(89)91148-0;
RA   Ito A., Hashimoto T., Hirai M., Takeda T., Shuntoh H., Kuno T., Tanaka C.;
RT   "The complete primary structure of calcineurin A, a calmodulin binding
RT   protein homologous with protein phosphatases 1 and 2A.";
RL   Biochem. Biophys. Res. Commun. 163:1492-1497(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, CATALYTIC ACTIVITY, AND
RP   ACTIVITY REGULATION.
RX   PubMed=1322410; DOI=10.1016/s0021-9258(19)49628-2;
RA   Perrino B.A., Fong Y.L., Brickey D.A., Saitoh Y., Ushio Y., Fukunaga K.,
RA   Miyamoto E., Soderling T.R.;
RT   "Characterization of the phosphatase activity of a baculovirus-expressed
RT   calcineurin A isoform.";
RL   J. Biol. Chem. 267:15965-15969(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19.
RC   TISSUE=Liver;
RX   PubMed=1335233; DOI=10.1042/bj2880801;
RA   Chang C., Takeda T., Mukai H., Shuntoh H., Kuno T., Tanaka C.;
RT   "Molecular cloning and characterization of the promoter region of the
RT   calcineurin A alpha gene.";
RL   Biochem. J. 288:801-805(1992).
RN   [4]
RP   PROTEIN SEQUENCE OF 143-148, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 236-306.
RX   PubMed=2174876; DOI=10.1016/s0021-9258(18)45767-5;
RA   Wadzinski B.E., Heasley L.E., Johnson G.L.;
RT   "Multiplicity of protein serine-threonine phosphatases in PC12
RT   pheochromocytoma and FTO-2B hepatoma cells.";
RL   J. Biol. Chem. 265:21504-21508(1990).
RN   [6]
RP   INTERACTION WITH CHP1.
RX   PubMed=10593895; DOI=10.1074/jbc.274.51.36125;
RA   Lin X., Sikkink R.A., Rusnak F., Barber D.L.;
RT   "Inhibition of calcineurin phosphatase activity by a calcineurin B
RT   homologous protein.";
RL   J. Biol. Chem. 274:36125-36131(1999).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11114196; DOI=10.1073/pnas.260501097;
RA   Frey N., Richardson J.A., Olson E.N.;
RT   "Calsarcins, a novel family of sarcomeric calcineurin-binding proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:14632-14637(2000).
RN   [8]
RP   INTERACTION WITH CHP2.
RX   PubMed=18815128; DOI=10.1074/jbc.m806684200;
RA   Li G.D., Zhang X., Li R., Wang Y.D., Wang Y.L., Han K.J., Qian X.P.,
RA   Yang C.G., Liu P., Wei Q., Chen W.F., Zhang J., Zhang Y.;
RT   "CHP2 activates the calcineurin/nuclear factor of activated T cells
RT   signaling pathway and enhances the oncogenic potential of HEK293 cells.";
RL   J. Biol. Chem. 283:32660-32668(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-469, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=23699505; DOI=10.1523/jneurosci.4288-12.2013;
RA   Kim S.H., Ryan T.A.;
RT   "Balance of calcineurin Aalpha and CDK5 activities sets release probability
RT   at nerve terminals.";
RL   J. Neurosci. 33:8937-8950(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 1-492, FUNCTION, CATALYTIC
RP   ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=24018048; DOI=10.1016/j.cellsig.2013.08.033;
RA   Ye Q., Feng Y., Yin Y., Faucher F., Currie M.A., Rahman M.N., Jin J.,
RA   Li S., Wei Q., Jia Z.;
RT   "Structural basis of calcineurin activation by calmodulin.";
RL   Cell. Signal. 25:2661-2667(2013).
CC   -!- FUNCTION: Calcium-dependent, calmodulin-stimulated protein phosphatase
CC       which plays an essential role in the transduction of intracellular
CC       Ca(2+)-mediated signals (PubMed:1322410, PubMed:24018048). Many of the
CC       substrates contain a PxIxIT motif and/or a LxVP motif (By similarity).
CC       In response to increased Ca(2+) levels, dephosphorylates and activates
CC       phosphatase SSH1 which results in cofilin dephosphorylation (By
CC       similarity). In response to increased Ca(2+) levels following
CC       mitochondrial depolarization, dephosphorylates DNM1L inducing DNM1L
CC       translocation to the mitochondrion (By similarity). Positively
CC       regulates the CACNA1B/CAV2.2-mediated Ca(2+) release probability at
CC       hippocampal neuronal soma and synaptic terminals (PubMed:23699505).
CC       Dephosphorylates heat shock protein HSPB1 (By similarity).
CC       Dephosphorylates and activates transcription factor NFATC1 (By
CC       similarity). Dephosphorylates and inactivates transcription factor ELK1
CC       (By similarity). Dephosphorylates DARPP32 (By similarity). May
CC       dephosphorylate CRTC2 at 'Ser-171' resulting in CRTC2 dissociation from
CC       14-3-3 proteins (By similarity). Required for postnatal development of
CC       the nephrogenic zone and superficial glomeruli in the kidneys, cell
CC       cycle homeostasis in the nephrogenic zone, and ultimately normal kidney
CC       function (By similarity). Plays a role in intracellular AQP2 processing
CC       and localization to the apical membrane in the kidney, may thereby be
CC       required for efficient kidney filtration (By similarity). Required for
CC       secretion of salivary enzymes amylase, peroxidase, lysozyme and sialic
CC       acid via formation of secretory vesicles in the submandibular glands
CC       (By similarity). Required for calcineurin activity and homosynaptic
CC       depotentiation in the hippocampus (By similarity). Required for normal
CC       differentiation and survival of keratinocytes and therefore required
CC       for epidermis superstructure formation (By similarity). Positively
CC       regulates osteoblastic bone formation, via promotion of osteoblast
CC       differentiation (By similarity). Positively regulates osteoclast
CC       differentiation, potentially via NFATC1 signaling (By similarity). May
CC       play a role in skeletal muscle fiber type specification, potentially
CC       via NFATC1 signaling (By similarity). Negatively regulates MAP3K14/NIK
CC       signaling via inhibition of nuclear translocation of the transcription
CC       factors RELA and RELB (By similarity). Required for antigen-specific T-
CC       cell proliferation response (By similarity). Dephosphorylates KLHL3,
CC       promoting the interaction between KLHL3 and WNK4 and subsequent
CC       degradation of WNK4 (By similarity). Negatively regulates SLC9A1
CC       activity (By similarity). {ECO:0000250|UniProtKB:P48452,
CC       ECO:0000250|UniProtKB:P63328, ECO:0000250|UniProtKB:Q08209,
CC       ECO:0000269|PubMed:1322410, ECO:0000269|PubMed:23699505,
CC       ECO:0000269|PubMed:24018048}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16; Evidence={ECO:0000269|PubMed:1322410,
CC         ECO:0000269|PubMed:24018048};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-threonyl-[protein] = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16; Evidence={ECO:0000269|PubMed:1322410,
CC         ECO:0000269|PubMed:24018048};
CC   -!- COFACTOR:
CC       Name=Fe(3+); Xref=ChEBI:CHEBI:29034;
CC         Evidence={ECO:0000250|UniProtKB:Q08209};
CC       Note=Binds 1 Fe(3+) ion per subunit. {ECO:0000250|UniProtKB:Q08209};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q08209};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q08209};
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)-bound calmodulin following an
CC       increase in intracellular Ca(2+) (PubMed:1322410, PubMed:24018048). At
CC       low Ca(2+) concentrations, the catalytic subunit (also known as
CC       calcineurin A) is inactive and is bound to the regulatory subunit (also
CC       known as calcineurin B) in which only two high-affinity binding sites
CC       are occupied by Ca(2+) (PubMed:1322410, PubMed:24018048). In response
CC       to elevated calcium levels, the occupancy of the low-affinity sites on
CC       calcineurin B by Ca(2+) causes a conformational change of the C-
CC       terminal regulatory domain of calcineurin A, resulting in the exposure
CC       of the calmodulin-binding domain and in the partial activation of
CC       calcineurin A (PubMed:1322410, PubMed:24018048). The subsequent binding
CC       of Ca(2+)-bound calmodulin leads to the displacement of the
CC       autoinhibitory domain from the active site and possibly of the
CC       autoinhibitory segment from the substrate binding site which fully
CC       activates calcineurin A (PubMed:1322410, PubMed:24018048). Inhibited by
CC       immunosuppressant drug FK506 (tacrolimus) in complex with FKBP12 and
CC       also by immunosuppressant drug cyclosporin A (CsA) in complex with
CC       PPIA/cyclophilin A; the inhibition is Ca(2+)-dependent (By similarity).
CC       {ECO:0000250|UniProtKB:P48452, ECO:0000269|PubMed:1322410,
CC       ECO:0000269|PubMed:24018048}.
CC   -!- SUBUNIT: Forms a complex composed of a calmodulin-dependent catalytic
CC       subunit (also known as calcineurin A) and a regulatory Ca(2+)-binding
CC       subunit (also known as calcineurin B) (By similarity). There are three
CC       catalytic subunits, each encoded by a separate gene (PPP3CA, PPP3CB,
CC       and PPP3CC) and two regulatory subunits which are also encoded by
CC       separate genes (PPP3R1 and PPP3R2). In response to an increase in
CC       Ca(2+) intracellular levels, forms a complex composed of
CC       PPP3CA/calcineurin A, calcineurin B and calmodulin (By similarity).
CC       Interacts (via calcineurin B binding domain) with regulatory subunit
CC       PPP3R1/calcineurin B (By similarity). Interacts (via calmodulin-binding
CC       domain) with calmodulin; the interaction depends on calmodulin binding
CC       to Ca(2+) (By similarity). Forms a complex composed of MYOZ2 and ACTN1
CC       (By similarity). Within the complex interacts with MYOZ2 (By
CC       similarity). Interacts with MYOZ1 (By similarity). Interacts with MYOZ3
CC       (By similarity). Interacts with CIB1; the interaction increases upon
CC       cardiomyocyte hypertrophy (By similarity). Interacts with CHP1 and CHP2
CC       (PubMed:10593895, PubMed:18815128). Interacts with CRTC1. Interacts
CC       with CRTC2 (By similarity). Interacts with DNM1L; the interaction
CC       dephosphorylates DNM1L and promotes its translocation to mitochondria
CC       (By similarity). Interacts with CMYA5; this interaction represses
CC       calcineurin activity in muscle (By similarity). Interacts
CC       (constitutively active form) with SYNPO2 (By similarity). Interacts
CC       with scaffold protein AKAP5 (via IAIIIT motif); the interaction
CC       recruits PPP3CA to the plasma membrane following L-type Ca(2+)-channel
CC       activation (By similarity). Interacts with NFATC2 (By similarity).
CC       Interacts with RCAN3 (By similarity). Interacts with PPIA. Interacts
CC       with RCAN1 (By similarity). Interacts with UNC119 (By similarity).
CC       Interacts with C16orf74 (via PxIxIT motif, when phosphorylated on 'Thr-
CC       76') (By similarity). Interacts (via N-terminus) with MAP3K14/NIK (via
CC       C-terminus and kinase domain) (By similarity). Interacts with TRAF3 (By
CC       similarity). Interacts with SPATA33 (via PQIIIT motif) (By similarity).
CC       {ECO:0000250|UniProtKB:P48452, ECO:0000250|UniProtKB:P63328,
CC       ECO:0000250|UniProtKB:Q08209, ECO:0000269|PubMed:10593895,
CC       ECO:0000269|PubMed:18815128}.
CC   -!- INTERACTION:
CC       P63329; P22002: Cacna1c; NbExp=5; IntAct=EBI-7022944, EBI-1185084;
CC       P63329; Q8VHW5: Cacng8; NbExp=6; IntAct=EBI-7022944, EBI-9086576;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q08209}. Cell
CC       membrane {ECO:0000250|UniProtKB:Q08209}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q08209}. Cell membrane, sarcolemma
CC       {ECO:0000269|PubMed:11114196}. Cytoplasm, myofibril, sarcomere, Z line
CC       {ECO:0000269|PubMed:11114196}. Cell projection, dendritic spine
CC       {ECO:0000250|UniProtKB:Q08209}. Note=Colocalizes with ACTN1 and MYOZ2
CC       at the Z line in heart and skeletal muscle (PubMed:11114196). Recruited
CC       to the cell membrane by scaffold protein AKAP5 following L-type Ca(2+)-
CC       channel activation (By similarity). {ECO:0000250|UniProtKB:Q08209,
CC       ECO:0000269|PubMed:11114196}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P63329-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P63329-2; Sequence=VSP_018564;
CC   -!- TISSUE SPECIFICITY: Expressed in neonatal cardiomyocytes (at protein
CC       level) (PubMed:11114196). Expressed in hippocampal presynaptic termini
CC       (at protein level) (PubMed:23699505). {ECO:0000269|PubMed:11114196,
CC       ECO:0000269|PubMed:23699505}.
CC   -!- DOMAIN: The autoinhibitory domain prevents access to the catalytic
CC       site. {ECO:0000250|UniProtKB:P63328}.
CC   -!- DOMAIN: The autoinhibitory segment prevents access to the substrate
CC       binding site. {ECO:0000250|UniProtKB:P63328}.
CC   -!- DOMAIN: Possible isomerization of Pro-309 within the SAPNY motif
CC       triggers a conformation switch which affects the organization and thus
CC       accessibility of the active site and the substrate binding region
CC       (PxIxIF motif). The trans- to cis-transition may favor calcineurin A
CC       activation and substrate binding. The reverse cis- to trans-transition
CC       may be enhanced by peptidyl-prolyl isomerases such as PPIA.
CC       {ECO:0000250|UniProtKB:Q08209}.
CC   -!- SIMILARITY: Belongs to the PPP phosphatase family. PP-2B subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D90035; BAA14083.1; -; mRNA.
DR   EMBL; M29275; AAA40940.1; -; mRNA.
DR   EMBL; X57115; CAA40398.2; -; mRNA.
DR   EMBL; D10480; BAA01283.1; -; Genomic_DNA.
DR   EMBL; M58440; AAA41914.1; -; mRNA.
DR   PIR; A33264; A33264.
DR   RefSeq; NP_058737.1; NM_017041.1. [P63329-1]
DR   RefSeq; XP_006233425.1; XM_006233363.3. [P63329-2]
DR   PDB; 4IL1; X-ray; 3.00 A; A/B/C/D=1-492.
DR   PDBsum; 4IL1; -.
DR   AlphaFoldDB; P63329; -.
DR   BMRB; P63329; -.
DR   SMR; P63329; -.
DR   BioGRID; 246806; 6.
DR   CORUM; P63329; -.
DR   IntAct; P63329; 6.
DR   MINT; P63329; -.
DR   STRING; 10116.ENSRNOP00000049674; -.
DR   GlyGen; P63329; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P63329; -.
DR   PhosphoSitePlus; P63329; -.
DR   SwissPalm; P63329; -.
DR   jPOST; P63329; -.
DR   PaxDb; 10116-ENSRNOP00000049674; -.
DR   Ensembl; ENSRNOT00000047975.6; ENSRNOP00000049674.6; ENSRNOG00000009882.8. [P63329-2]
DR   Ensembl; ENSRNOT00000105262.1; ENSRNOP00000082751.1; ENSRNOG00000009882.8. [P63329-1]
DR   GeneID; 24674; -.
DR   KEGG; rno:24674; -.
DR   AGR; RGD:3382; -.
DR   CTD; 5530; -.
DR   RGD; 3382; Ppp3ca.
DR   eggNOG; KOG0375; Eukaryota.
DR   GeneTree; ENSGT00940000156306; -.
DR   HOGENOM; CLU_004962_6_0_1; -.
DR   InParanoid; P63329; -.
DR   OrthoDB; 1488111at2759; -.
DR   PhylomeDB; P63329; -.
DR   BRENDA; 3.1.3.16; 5301.
DR   Reactome; R-RNO-2025928; Calcineurin activates NFAT.
DR   Reactome; R-RNO-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-RNO-4086398; Ca2+ pathway.
DR   Reactome; R-RNO-5607763; CLEC7A (Dectin-1) induces NFAT activation.
DR   EvolutionaryTrace; P63329; -.
DR   PRO; PR:P63329; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000009882; Expressed in Ammon's horn and 19 other cell types or tissues.
DR   GO; GO:0005955; C:calcineurin complex; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0098794; C:postsynapse; ISO:RGD.
DR   GO; GO:0042383; C:sarcolemma; IEA:UniProtKB-SubCell.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISO:RGD.
DR   GO; GO:0036057; C:slit diaphragm; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IDA:SynGO.
DR   GO; GO:0030018; C:Z disc; ISO:RGD.
DR   GO; GO:0051117; F:ATPase binding; ISO:RGD.
DR   GO; GO:0004723; F:calcium-dependent protein serine/threonine phosphatase activity; IDA:RGD.
DR   GO; GO:0005516; F:calmodulin binding; IDA:RGD.
DR   GO; GO:0033192; F:calmodulin-dependent protein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0016018; F:cyclosporin A binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017018; F:myosin phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:RGD.
DR   GO; GO:0046983; F:protein dimerization activity; ISO:RGD.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0097720; P:calcineurin-mediated signaling; ISO:RGD.
DR   GO; GO:0033173; P:calcineurin-NFAT signaling cascade; ISO:RGD.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISO:RGD.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; ISO:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IMP:BHF-UCL.
DR   GO; GO:0048813; P:dendrite morphogenesis; ISO:RGD.
DR   GO; GO:0008544; P:epidermis development; ISS:UniProtKB.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; ISO:RGD.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0030216; P:keratinocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISS:UniProtKB.
DR   GO; GO:0033555; P:multicellular organismal response to stress; ISO:RGD.
DR   GO; GO:0110062; P:negative regulation of angiotensin-activated signaling pathway; ISO:RGD.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IC:BHF-UCL.
DR   GO; GO:0050774; P:negative regulation of dendrite morphogenesis; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IMP:BHF-UCL.
DR   GO; GO:0023057; P:negative regulation of signaling; ISS:UniProtKB.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISO:RGD.
DR   GO; GO:1903244; P:positive regulation of cardiac muscle hypertrophy in response to stress; ISO:RGD.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISO:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:RGD.
DR   GO; GO:1905205; P:positive regulation of connective tissue replacement; ISO:RGD.
DR   GO; GO:0045807; P:positive regulation of endocytosis; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0090193; P:positive regulation of glomerulus development; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0046878; P:positive regulation of saliva secretion; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:RGD.
DR   GO; GO:0061006; P:regulation of cell proliferation involved in kidney morphogenesis; ISS:UniProtKB.
DR   GO; GO:0097205; P:renal filtration; ISS:UniProtKB.
DR   GO; GO:0001975; P:response to amphetamine; IEP:RGD.
DR   GO; GO:0051592; P:response to calcium ion; ISS:UniProtKB.
DR   GO; GO:0048741; P:skeletal muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0014883; P:transition between fast and slow fiber; ISO:RGD.
DR   CDD; cd07416; MPP_PP2B; 1.
DR   Gene3D; 3.60.21.10; -; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_ApaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR041751; MPP_PP2B.
DR   InterPro; IPR043360; PP2B.
DR   InterPro; IPR006186; Ser/Thr-sp_prot-phosphatase.
DR   PANTHER; PTHR45673:SF5; PROTEIN PHOSPHATASE 3 CATALYTIC SUBUNIT ALPHA; 1.
DR   PANTHER; PTHR45673; SERINE/THREONINE-PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT 1-RELATED; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   PRINTS; PR00114; STPHPHTASE.
DR   SMART; SM00156; PP2Ac; 1.
DR   SUPFAM; SSF56300; Metallo-dependent phosphatases; 1.
DR   PROSITE; PS00125; SER_THR_PHOSPHATASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calmodulin-binding;
KW   Cell membrane; Cell projection; Cytoplasm; Direct protein sequencing;
KW   Hydrolase; Iron; Membrane; Metal-binding; Nitration; Phosphoprotein;
KW   Protein phosphatase; Reference proteome; Synapse; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   CHAIN           2..521
FT                   /note="Protein phosphatase 3 catalytic subunit alpha"
FT                   /id="PRO_0000058824"
FT   REGION          56..340
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000305"
FT   REGION          327..336
FT                   /note="Interaction with PxIxIF motif in substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   REGION          341..369
FT                   /note="Calcineurin B binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   REGION          392..406
FT                   /note="Calmodulin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   REGION          407..414
FT                   /note="Autoinhibitory segment"
FT                   /evidence="ECO:0000250|UniProtKB:P16298"
FT   REGION          465..487
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000269|PubMed:1322410"
FT   REGION          475..521
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           307..311
FT                   /note="SAPNY motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   COMPBIAS        493..521
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         90
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         92
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         118
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         118
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         150
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         199
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         281
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   SITE            352
FT                   /note="Interaction with PxVP motif in substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   MOD_RES         224
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P63328"
FT   MOD_RES         469
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         492
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   VAR_SEQ         448..457
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1322410"
FT                   /id="VSP_018564"
FT   HELIX           31..34
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           43..51
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           58..72
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          77..81
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          83..88
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           95..105
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          120..123
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           126..139
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            141..143
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          144..146
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           154..159
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           162..168
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           172..184
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          188..191
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            192..194
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          195..200
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           209..213
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           226..232
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            237..240
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          247..250
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            252..255
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          256..260
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           262..271
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          275..279
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          287..290
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   TURN            295..297
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          299..306
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           311..313
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          319..325
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   STRAND          328..334
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           344..346
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           349..366
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           473..476
FT                   /evidence="ECO:0007829|PDB:4IL1"
FT   HELIX           478..481
FT                   /evidence="ECO:0007829|PDB:4IL1"
SQ   SEQUENCE   521 AA;  58644 MW;  16530C27DDBF1F05 CRC64;
     MSEPKAIDPK LSTTDRVVKA VPFPPSHRLT AKEVFDNDGK PRVDILKAHL MKEGRLEESV
     ALRIITEGAS ILRQEKNLLD IDAPVTVCGD IHGQFFDLMK LFEVGGSPAN TRYLFLGDYV
     DRGYFSIECV LYLWALKILY PKTLFLLRGN HECRHLTEYF TFKQECKIKY SERVYDACMD
     AFDCLPLAAL MNQQFLCVHG GLSPEINTLD DIRKLDRFKE PPAYGPMCDI LWSDPLEDFG
     NEKTQEHFTH NTVRGCSYFY SYPAVCDFLQ HNNLLSILRA HEAQDAGYRM YRKSQTTGFP
     SLITIFSAPN YLDVYNNKAA VLKYENNVMN IRQFNCSPHP YWLPNFMDVF TWSLPFVGEK
     VTEMLVNVLN ICSDDELGSE EDGFDGATAA ARKEVIRNKI RAIGKMARVF SVLREESESV
     LTLKGLTPTG MLPSGVLSGG KQTLQSATVE AIEADEAIKG FSPQHKITSF EEAKGLDRIN
     ERMPPRRDAM PSDANLNSIN KALASETNGT DSNGSNSSNI Q
//
